Yamanouchi Announces Incorporation of Drug Delivery Technologies Subsidiary

Yamanouchi Pharmaceutical Co. Ltd. (Palo Alto, CA) announced today the incorporation of its drug delivery technologies subsidiary, Yamanouchi Pharma Technologies Inc. This newly-incorporated entity is the same unit which has to date been conducting its business as Yamanouchi Pharma Technologies, Inc. and YSPharma. Yamanouchi Pharma Technologies will continue its primary responsibility for the worldwide introduction and commercialization of novel drug delivery technologies, partnering with multinational pharmaceutical companies. Considerable progress has been made thus far in establishing its business with its premier technologies—WOWTAB, the without-water oral disintegrating tablet, the controlled release system, OCAS, and the colon-targeted release system, CODES.

"We look forward to continuing our charge of creating breakthroughs in drug delivery, building on our initial successes," said Dan Green, president and COO. "We greatly value Yamanouchi's confidence in and consistent support of our efforts to develop our business."

"This strategic realignment of Yamanouchi Pharma Technologies, Inc., provides valuable operational autonomy, while providing more immediate lines of communication with Yamanouchi," emphasized Masayoshi Onoda, president and CEO of Yamanouchi Pharmaceutical Co. Ltd. "We look forward to continued advances in both drug delivery technology innovation and business growth."

Yamanouchi Pharma Technologies Inc., located in the Stanford Research Park in Palo Alto, CA, was formerly a division of San Francisco Bay Area-based Shaklee Corp., and will now join Shaklee as a wholly-owned subsidiary of Yamanouchi. Founded in 1923, Yamanouchi Pharmaceutical Co. Ltd. has established an international reputation as a research-oriented company and as a leader in the pharmaceuticals industry. With operations worldwide, Yamanouchi ranks third in sales in the Japanese pharmaceutical market.